SCHEDULE 13G: Bigger Capital Divests Entire 6.2% Stake in Aptevo Therapeutics
Beneficial Ownership Disclosure
Bigger Capital Fund L P, Bigger Capital Fund GP, LLC, and Michael Bigger have disclosed the sale of their entire 6.2% beneficial ownership in Aptevo Therapeutics Inc. common stock as of April 3, 2025.
Summary
- Bigger Capital Fund L P, Bigger Capital Fund GP, LLC, and Michael Bigger (collectively, the "Reporting Persons") filed a Schedule 13G regarding their beneficial ownership in Aptevo Therapeutics Inc.
- As of April 3, 2025, the Reporting Persons beneficially owned 200,000 shares of Aptevo Therapeutics Inc. Common Stock.
- This ownership represented 6.20% of the outstanding Common Stock, based on 3,223,214 shares outstanding immediately after a recent offering.
- Crucially, the filing states that as of the close of business on April 3, 2025, the Reporting Persons sold all of their Common Stock.
- Consequently, as of April 3, 2025, the Reporting Persons are no longer beneficial owners of at least 5.00% of Aptevo Therapeutics Inc.'s Common Stock.
- The Reporting Persons also hold 859,776 shares of Common Warrants, which are not currently exercisable and are subject to a 4.99% beneficial ownership limitation.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative as a significant institutional investor has fully divested its stake, which can be perceived as a lack of confidence or a strategic exit, potentially impacting market perception of the stock.
Negatives
- A significant institutional investor, Bigger Capital, has fully divested its 6.20% stake in Aptevo Therapeutics Inc. common stock, which could be perceived negatively by the market.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding Aptevo Therapeutics Inc.'s operations or financial performance.
Management Comments
- "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Signed by Michael Bigger for Bigger Capital Fund L P, Bigger Capital Fund GP, LLC, and himself).
Industry Context
This filing is a standard disclosure of a change in beneficial ownership by an institutional investor and does not provide broader industry trend analysis or competitive insights.
Stakeholder Impact
- Shareholders may react to the news of a significant institutional investor selling its entire stake, potentially leading to negative sentiment or downward pressure on the stock price.
Key Dates
| Date | Description |
|---|---|
| 04/03/2025 | Date of event which required the filing of this statement, specifically the sale of all Common Stock by the Reporting Persons. |
| 04/04/2025 | Date of the Issuer's Prospectus filing under Rule 424(b)(4) with the SEC, related to a recent offering. |
| 04/08/2025 | Date the Schedule 13G filing was executed and dated by the Reporting Persons. |
Keywords
Aptevo Therapeutics, Schedule 13G, beneficial ownership, institutional investor, Michael Bigger, Bigger Capital, common stock, divestment, equity stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.